Obviousness

Obviousness Analysis under 35 U.S.C. § 103 for US Patent 11013729

An invention is obvious under 35 U.S.C. § 103 if the differences between the claimed invention and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art (PHOSITA). This analysis considers: (1) the scope and content of the prior art; (2) the differences between the claimed invention and the prior art; (3) the level of ordinary skill in the pertinent art; and (4) secondary considerations of non-obviousness.

1. Independent Claims

The independent claims of US 11013729 are Claims 1, 11, and 16. Their key elements are:

• Claim 1: A composition comprising a mixture of at least two distinct types of particles. The first type comprises dabigatran etexilate (or its pharmaceutically acceptable salt/polymorph) and is free from organic and inorganic acids. The second type comprises at least one pharmaceutically acceptable organic acid, is coated with a protective coating layer, and is free from dabigatran etexilate.
• Claim 11: A composition consisting of a mixture of two distinct types of particles (as defined in Claim 1) and at least one pharmaceutically acceptable excipient.
• Claim 16: A capsule containing a pharmaceutical composition consisting of a mixture of two distinct types of particles (as defined in Claim 1) and at least one pharmaceutically acceptable excipient.

The core inventive concept across these claims is the physical separation of acid-sensitive dabigatran etexilate into one particle type (which is acid-free) and a pharmaceutically acceptable organic acid into a second, distinct particle type (which is coated and active-free), followed by mixing these two particle types.

2. Scope and Content of the Prior Art

The patent itself identifies several relevant prior art documents:

• U.S. Patent Application 2006/0183779A1: This application describes pharmaceutical compositions of dabigatran etexilate mesylate (DEM) for oral administration in the form of pellets. These pellets comprise an acidic core (e.g., tartaric acid) and an active substance layer (DEM) that encloses the core. Optionally, a separating agent layer is placed between the acid core and the active layer, and the active layer may be further enclosed in an outer coating. The patent states that "the process of preparing layered pellets is cumbersome, time consuming and uneconomical."
• U.S. Patent Application 2005/0038077 (and WO 03/074056): This application discloses a tablet containing dabigatran etexilate (or a pharmaceutically acceptable salt thereof) and one or more pharmaceutically acceptable organic acids. The patent criticizes this approach, stating that "due to the presence of an organic acid in close contact with the active in a tablet composition without any special steps taken to separate the two from each other, can make the active highly susceptible to hydrolysis in the presence of humidity." Example 3 of US 11013729 explicitly refers to "Formulation B" as being prepared according to WO 03/074056, particularly Example 1, which represents a formulation having "one type of particles/pellets having both dabigatran etexilate mesylate and organic acid."
• WO98/37075: First disclosed dabigatran.
• WO 2005/028468: Describes anhydrous polymorphic forms I and II of dabigatran etexilate mesylate.

General knowledge in the art at the time of the invention (priority date 2012-02-21) would include common pharmaceutical excipients, granulation techniques (wet, dry, melt), extrusion-spheronization for pellets, and various coating methods and materials for taste-masking, protection, or controlled release.

3. Differences Between the Claimed Invention and the Prior Art

The primary difference lies in the physical arrangement of the active pharmaceutical ingredient (dabigatran etexilate) and the organic acid.

• U.S. Patent Application 2005/0038077 / WO 03/074056 teaches compositions where dabigatran etexilate and the organic acid are in direct contact within a single particle type (e.g., a tablet or a pellet where both are mixed).
• U.S. Patent Application 2006/0183779A1 teaches layered pellets where an active substance layer encloses an acid core, potentially with an intermediate separating layer and an outer coating. This still constitutes a single composite particle with the acid and active in close proximity, even if separated by a thin layer.

In contrast, US 11013729 claims a mixture of at least two distinct types of particles: one containing the active (acid-free) and a separate one containing the organic acid (active-free and coated).

4. Level of Ordinary Skill in the Art (PHOSITA)

A PHOSITA in the field of oral pharmaceutical formulations at the time of the invention would likely have a Master's or Ph.D. in pharmaceutical sciences, chemistry, or a related field, with practical experience in drug development, formulation, and manufacturing. They would be familiar with the physicochemical properties of drugs, including pH-dependent solubility, stability issues (e.g., hydrolysis), and techniques to address these challenges in oral dosage forms. They would also understand the role of organic acids in enhancing the bioavailability of certain drugs and various methods for particle preparation and coating.

5. Motivation to Combine/Modify Prior Art

The background of US 11013729 clearly articulates the problems associated with dabigatran etexilate, stating that it "predominantly undergoes degradation by hydrolytic pathways in the presence of moisture" and is "acid sensitive."

The patent itself provides the motivation for a PHOSITA to combine or modify the existing prior art:

1. Addressing Instability due to Direct Acid Contact: U.S. Patent Application 2005/0038077 is explicitly criticized for allowing "an organic acid in close contact with the active," leading to the active being "highly susceptible to hydrolysis in the presence of humidity." A PHOSITA, faced with this known problem of dabigatran etexilate's acid sensitivity, would be motivated to physically separate the active from the organic acid. Instead of merely using a separating layer within a single particle (as in some embodiments of US 2006/0183779A1), creating entirely distinct particles for each component would be an obvious way to maximize this separation and minimize direct contact.
2. Improving upon "Cumbersome" Layered Pellets: U.S. Patent Application 2006/0183779A1 teaches layered pellets, which the present patent describes as "cumbersome, time consuming and uneconomical." A PHOSITA would seek simpler, more efficient manufacturing processes. Preparing two separate particle types (e.g., by granulation and/or extrusion-spheronization, as described in the present patent's examples) and then blending them is a well-known and often simpler approach compared to multi-layer coating processes.
3. Benefits of Organic Acid Maintenance: Both U.S. Patent Application 2006/0183779A1 and U.S. Patent Application 2005/0038077 acknowledge the benefit of including an organic acid with dabigatran etexilate for its pH-dependent solubility characteristics. The motivation would be to retain this beneficial effect while mitigating the stability issues.
4. Known Pharmaceutical Techniques: Coating of particles (including acid pellets) is a standard technique in pharmaceutical formulation to protect components, control release, or mask taste. Given the acid sensitivity of dabigatran etexilate and its proneness to hydrolytic degradation, a PHOSITA would be motivated to protect the more vulnerable component or prevent unwanted interactions. Coating the organic acid particles, as claimed, would prevent the acid from readily interacting with the dabigatran etexilate particles or with moisture in the environment, further enhancing overall stability while still providing the acidic microenvironment upon dissolution.
5. Achieving Faster Dissolution: The patent itself states a goal of providing "quick dissolution particularly at earlier time points" to enhance active absorption., A PHOSITA would understand that different particle sizes and formulations can influence dissolution profiles. Creating separate, optimized particles could be a way to achieve a desired dissolution characteristic.

Specific Combinations:

• U.S. Patent Application 2005/0038077 (or WO 03/074056) + General Knowledge of Dabigatran Stability + Standard Coating Techniques: Given the explicit problem of instability caused by direct contact between dabigatran etexilate and organic acid in a single formulation (as taught by US'077 and exemplified by Formulation B), a PHOSITA would be motivated to separate these components. Creating distinct particles for the active and the acid, and further coating the acid particles (a well-known protective measure), would be an obvious way to overcome the identified stability issues while retaining the benefit of the acid environment upon dissolution.
• U.S. Patent Application 2006/0183779A1 + General Knowledge of Manufacturing Efficiency & Particle Formulation: Recognizing the "cumbersome" nature of layered pellets from US'779, a PHOSITA would seek a simpler manufacturing method that still provides the benefits of acid. Producing separate active-containing granules and coated acid pellets, then blending them, would be an obvious alternative approach to achieve component separation and enhance stability without the complexity of multi-layering within a single particle.

6. Secondary Considerations

The patent presents an "unexpected result" in Example 3, demonstrating that "Formulation A" (the claimed invention with two distinct types of particles) provides "faster dissolution particularly at earlier time points as compared to formulation having one type of particles/pellets (Formulation B)." For instance, at 10 minutes, Formulation A released 65.1% of the active, while Formulation B released only 19.2%. This improved early dissolution profile is presented as an advantage, ensuring "availability of more amount of active especially when (a) absorption of the active is rapid... (b) significant bioactivation is involved and (c) negligible and variable absorption at higher pH.",

While the motivation for separating the active and acid to improve stability and simplify manufacturing seems apparent to a PHOSITA, the significantly faster dissolution at earlier time points shown in Example 3 could be argued as an unexpected result, potentially weighing against a finding of obviousness. However, faster dissolution can sometimes be an expected outcome of certain particle formulations and coatings. The extent to which this specific improvement is truly "unexpected" would be a key point of contention.